Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

677
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
677
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.1K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.1K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.1K
Gene Therapy00:59

Gene Therapy

26.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
26.4K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.8K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

513
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
513

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bioenergetic dysregulation in the basal ganglia and cerebellum of patients with premanifest and manifest Huntington's disease.

Neurobiology of disease·2026
Same author

In-vivo iron mapping in patients with Parkinson's disease using deep learning-based susceptibility source separation MRI.

NPJ Parkinson's disease·2026
Same author

Deep-learning saturation transfer magnetic resonance fingerprinting (ST-MRF) in patients with Parkinson's disease.

NeuroImage·2026
Same author

Metabolic and Volumetric Alterations in the Basal Ganglia and the Cerebellum in Dopa-Responsive Dystonia in Symptomatic and Asymptomatic GCH1 Mutation Carriers.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

In-vivo histology of Parkinson's disease using quantitative multiparametric mapping.

NPJ Parkinson's disease·2026
Same author

The Movement Disorder Spectrum of ATP1A3-Related Disorders: Cross-Sectional Analysis and Video Archive of 88 Patients.

Movement disorders : official journal of the Movement Disorder Society·2026

Related Experiment Video

Updated: Nov 8, 2025

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons
09:21

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons

Published on: July 7, 2023

1.8K

Genotype-driven therapeutic developments in Parkinson's disease.

Jannik Prasuhn1,2,3, Norbert Brüggemann4,5,6

  • 1Department of Neurology, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.

Molecular Medicine (Cambridge, Mass.)
|April 20, 2021
PubMed
Summary
This summary is machine-generated.

Genetic discoveries are advancing Parkinson's disease (PD) understanding, revealing molecular mechanisms and paving the way for personalized, pathophysiology-targeted treatments and clinical trials.

Keywords:
GBAGeneticLRRK2MonogenicPINK1PRKN (Parkin)Parkinson’s diseaseSNCATherapyTranslationalTreatment

More Related Videos

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.2K
Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
08:33

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

13.5K

Related Experiment Videos

Last Updated: Nov 8, 2025

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons
09:21

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons

Published on: July 7, 2023

1.8K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.2K
Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
08:33

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

13.5K

Area of Science:

  • Neurogenetics
  • Molecular Biology
  • Clinical Trials

Background:

  • Significant progress in understanding Parkinson's disease (PD) genetics, including monogenic causes (mPD) and risk loci for idiopathic PD.
  • Identification of genetic factors enhances comprehension of molecular pathways in PD development and progression.
  • Key pathways implicated include mitochondrial dysfunction, oxidative stress, and lysosomal function, offering potential for personalized medicine.

Purpose of the Study:

  • To review genetic contributors to Parkinson's disease pathophysiology.
  • To elucidate molecular mechanisms underlying PD development.
  • To discuss challenges and opportunities in designing clinical trials for PD.

Main Methods:

  • Literature review of genetic studies in Parkinson's disease.
  • Analysis of molecular mechanisms linked to identified genetic factors.
  • Discussion of clinical trial design strategies informed by genetic findings.

Main Results:

  • Numerous genetic factors identified for PD, including monogenic causes and risk loci.
  • Established links between genetic variations and key cellular pathways (mitochondria, oxidative stress, lysosomes).
  • Genetic insights are driving progress toward pathophysiology-targeted therapies.

Conclusions:

  • Future clinical trial success in PD hinges on biomarker development and genetic testing.
  • Genotype-dependent stratification of participants presents both challenges and opportunities for drug application.
  • Advancements in genotype-driven treatments are crucial for developing individualized, pathophysiology-based therapies for Parkinson's disease.